• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Fondaparinux effective as antithrombotic therapy in NSTEMI

byMilana Bogorodskaya, MDandPriyanka Vedak
February 18, 2015
in Cardiology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Fondaparinux had a lower risk of in-hospital and post-hospitalization bleeding events and death compared to low molecular weight heparin (LMWH) treatment.

2. There was no difference in recurrence of myocardial infarction and stroke between the two groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: In 2007, based on the prior OASIS-5 study, the European Society of Cardiology recommended fondaparinux as the first-choice anticoagulant to treat patients who presented with an NSTEMI. This study was a prospective cohort study performed in Sweden from 2006-2010 that looked at the outcomes of patients with NSTEMI who received LMWH versus fondaparinux as antithrombotic therapy during their hospitalizations.

The study showed that fondaparinux was associated with lower rates of in-hospital death and bleeding as well as in follow-up to 180 days post-hospitalization. There was no difference seen between fondaparinux and LMWH for risk of recurrent MI and stroke up to 180 days post-hospitalization. The strength of the study lies in its population-based design. Weaknesses of the study include its observational design, which limits its ability to determine causality and makes it subject to confounding. However, the study did account for variables such as baseline kidney function, past cardiac history, and history of prior cardiac interventions. In summary, this study supported the findings of the OASIS-5 study and supports the use of fondaparinux in patients with NSTEMI.

Click to read the study, published today in JAMA

Relevant Reading: Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes

RELATED REPORTS

Oral P2Y12 inhibitor pretreatment offers no benefit in non-ST elevation acute coronary syndromes

#VisualAbstract: No significant differences in outcomes between pre- and post-treatment administration of P2Y12 inhibitors for NSTE-ACS

Association of body mass index and extreme obesity with long-term outcomes following percutaneous coronary intervention

In-Depth [prospective cohort]: This study is a prospective cohort study that included 40,616 patients from 2006-2010 in Sweden who were treated either with LMWH or fondaparinux as antithrombotic therapy for an NSTEMI. All patients above 18 were included with no exclusions based on past medical history. However, odds ratios for risk were adjusted for baseline characteristics that included renal function as well as history of coronary arterial disease intervention (e.g., percutaneous and surgical interventions). Outcome measures included in-hospital severe bleeding events and death, 30- and 180-day major bleeding events, death, stroke, and recurrent myocardial infarction (MI). The rate of severe in-hospital bleeding events was lower in the fondaparinux group (OR 0.54, 95%CI 0.42-0.70). This group also was also found to have a lower risk of bleeding or death at 30- and 180-days post-hospitalization (OR 0.74, 95%CI 0.65-0.84; OR 0.72, 95%CI 0.65-0.80, respectively). The fondaparinux group also had a lower risk of death post-hospitalization both at 30 and 180 days. There was no difference in MI or stroke recurrence between the two groups.

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: nstemi
Previous Post

Varenicline therapy increases smoking cessation rates

Next Post

Combined MRI and NIH stroke scores may predict stroke prognosis

RelatedReports

Propofol appears safe and effective in procedural sedation for cardioversion
Cardiology

Oral P2Y12 inhibitor pretreatment offers no benefit in non-ST elevation acute coronary syndromes

May 13, 2022
#VisualAbstract: No significant differences in outcomes between pre- and post-treatment administration of P2Y12 inhibitors for NSTE-ACS
StudyGraphics

#VisualAbstract: No significant differences in outcomes between pre- and post-treatment administration of P2Y12 inhibitors for NSTE-ACS

September 17, 2020
Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors
Cardiology

Association of body mass index and extreme obesity with long-term outcomes following percutaneous coronary intervention

November 3, 2019
Fibrosis linked with mortality in nonischemic dilated cardiomyopathy patients
Cardiology

Troponin criteria missed 26% of NSTEMIs

August 9, 2013
Next Post
Combined MRI and NIH stroke scores may predict stroke prognosis

Combined MRI and NIH stroke scores may predict stroke prognosis

Amyloid may cause distant cerebral hypometabolism in Alzheimer’s

Amyloid may cause distant cerebral hypometabolism in Alzheimer’s

Multiple opioid prescriptions associated with higher hospital admissions

Long-acting opioid use linked to higher risk of overdose

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
  • The RAPTURE trial: Radiofrequency ablation effective and safe in lung cancer [Classics Series]
  • Relugolix combination therapy is efficacious for endometriosis-associated pain
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.